A loss of $-0.42 per Share at the Cytomx Therapeutics Inc in fourth quarter of 2022

Underlining the most recent fiscal period the Major Pharmaceutical Preparations company lost money at $-0.42 per share, relative to the recent numbers of $-0.91 per share a year before reporting season, In the prior reporting season the Cytomx Therapeutics Inc realized $-0.35 per share.

Revenue Tumbled by -94.401 % from $16.92 million in the previous reporting season, grew loss from $-0.35 per share.


In the fourth quarter of 2022 Cytomx Therapeutics Inc reported net loss of $-27.952 million, instead of deficit of $-58.489 million in the same reporting season a year ago.

Furthermore, the Cytomx Therapeutics Inc claimed as well a shortfall of $-99.32 million and for the fiscal year 2022, revenue of $53.16 million.

Major Pharmaceutical Preparations Cytomx Therapeutics Inc has decreased it's loss per share to $-1.51 from $-1.81 in the prior fiscal year, while revenue surged by 42.48 % from $37.31 million a year before.

Cytomx Therapeutics Inc is expected to report next financial recent numbers on May 04, 2023.

Cytomx Therapeutics Inc's Price to earnings ratio PE

Cytomx Therapeutics Inc's Operating Margin

Other CTMX's Earnings Reports

The company declared a -3.821 %, reduction in revenue, all along the third quarter of 2022